Colorado Study Tests Covering Medical Cannabis in Workers’ Comp

A Colorado state agency has run what it calls a first-of-its-kind experiment: reimbursing an injured worker’s medical cannabis, under close clinical supervision, through the workers’ compensation system. The evaluation, published¹ in May 2026 in the Journal of Occupational & Environmental Medicine, followed a single patient for a year and recorded lower pain, better physical function, higher quality of life, and a voluntary 17 percent drop in opioid use, with no adverse safety events.

The work came from the Colorado Division of Workers’ Compensation and its Alternative Pain Management Program. Its authors are careful about what it does and does not show. This was not a clinical trial designed to prove that cannabis works for pain. It was a program evaluation, a proof-of-concept built to answer a narrower question: can a workers’ compensation system reimburse medical cannabis safely, under real medical oversight, for a patient already using it?

One patient, rigorously screened

The number that frames everything else is the sample size. Of more than 200 legacy claimants the division screened, exactly one met the baseline criteria for safety and compliance. That makes the study a case report, not evidence of a population-level effect. A single case cannot tell you how often cannabis reduces opioid use, by how much, or in whom. What it can do is show whether a reimbursement model is workable in practice, and this one was.

The design leaned heavily on structure. The participant’s authorized treating physician kept overall clinical responsibility and ran routine screenings, while a separate cannabis-trained physician handled dosing, titration, and cannabinoid ratios. Only precisely dosed oral products, such as gummies, were eligible for reimbursement; smoked and vaporized forms were excluded to limit respiratory risk and keep dosing standardized. The patient logged adherence through a cannabis-tracking app so the care team could monitor real-time use.

What the year showed

Across the 12-month window, the division recorded measurable reductions in pain and gains in mobility, physical function, and quality of life. Psychological status was tracked throughout and stayed stable. No concerning drug interactions or safety events were reported.

Opioid reduction was not the program’s primary goal, and no tapering was required. Even so, the researchers reported that better symptom control under supervision led the participant to cut monthly opioid intake by about 17 percent. After the study data were finalized, the division said, the patient moved off both opioids and THC entirely, relying only on less psychoactive cannabinoids. The study’s own conclusion stays deliberately modest: medical cannabis reimbursement “may be a viable option for very select workers’ compensation patients.”

The gap the program was built to close

Ethan Moses, the division’s medical director and the study’s lead author, has said he approached the project as a skeptic. He told the Denver outlet Westword that “the medical literature is really quite mixed on the efficacy of cannabis for lots of health conditions,” a state of affairs he attributes largely to cannabis’s long classification as a Schedule I drug, which has throttled rigorous research for years.

That framing is the point. The program was designed less to demonstrate efficacy than to close two practical gaps. The first is safety: many injured workers already manage pain with cannabis they buy themselves and hide from their doctors, outside any clinical oversight. The second is equity: alternative therapies tend to be available only to patients who can pay out of pocket after conventional treatment stops working. Bringing cannabis use into a supervised, reimbursed framework addresses both at once.

A policy backdrop moving the other way

The timing is pointed. In June 2026, a congressional committee voted to bar cannabis from federal workers’ compensation coverage, regardless of the Trump administration’s move to reclassify state-program medical marijuana as Schedule III. Colorado’s finding cuts against that current, but its reach is limited: state officials note they cannot require any insurer to cover cannabis, which is why keeping the arrangement voluntary was essential.

The single case sits within a larger, more suggestive body of work. Earlier research has linked medical cannabis laws to fewer missed workdays and to lower workers’ compensation costs and reduced opioid prescribing, and a separate line of clinical work has tied medical cannabis to reduced opioid use among chronic pain patients. None of that settles the efficacy question, and neither does Colorado’s evaluation.

The division is candid about the limits. The participant was fully retired, so the results say nothing about safety for people in active or safety-sensitive jobs. The model was resource-intensive, requiring sustained clinical coordination that would be hard to scale. And with one patient, the findings cannot be generalized. What Colorado has produced is a template and a hypothesis worth testing at scale, not a verdict.

References:

^{1. Moses, Xavier James Ethan; Ilsley, Blair; Greenlee, Megan; Golden, Katherine; Shackelford, Alan E.; Cassin, Mariya; Cook-Shimanek, Maggie; Foster, Roy; Grayek, Emily; and Hill, Juliana, “Medical Cannabis Reimbursement in Workers’ Compensation: Insights From a Program Evaluation in Colorado” (2026). Journal of Occupational & Environmental Medicine, 68(5), e325–e330. https://doi.org/10.1097/JOM.0000000000003675}